An open-label, single-arm, phase2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman, Sagar Lonial, Andrzej J. Jakubowiak, A. Keith Stewart, Vishal Kukreti, Sundar Jagannath, Kevin T. McDonagh, Melissa Alsina, Nizar J. Bahlis, Frederic J. Reu, Nashat Y. Gabrail, Andrew Belch, Jeffrey V. Matous, Peter Lee, Peter Rosen, Michael Sebag, David H. Vesole, Lori A. KunkelSandra M. Wear, Alvin F. Wong, Robert Z. Orlowski, David S. Siegel

Research output: Contribution to journalArticlepeer-review

224 Scopus citations

Fingerprint

Dive into the research topics of 'An open-label, single-arm, phase2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds